 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 GLOBE NEWSWIRE -- MannKind Corporation Nasdaq: MNKD, a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022. 